• No results found

University of Groningen Circulating tumor cells and the micro-environment in non-small cell lung cancer Tamminga, Menno

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Circulating tumor cells and the micro-environment in non-small cell lung cancer Tamminga, Menno"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Circulating tumor cells and the micro-environment in non-small cell lung cancer

Tamminga, Menno

DOI:

10.33612/diss.132713141

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Tamminga, M. (2020). Circulating tumor cells and the micro-environment in non-small cell lung cancer. University of Groningen. https://doi.org/10.33612/diss.132713141

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Stellingen:

- De afkapwaarde voor CTC in niet-kleincellig longkanker moet worden vastgesteld op 1 CTC per 7.5mL bloed.

- Patiënten met niet-kleincellig long carcinoom reageren minder goed op chemotherapie, targeted therapie en immuun modulerende therapie wanneer er circulerende tumor cellen worden gedetecteerd in hun perifere bloed. (dit proefschrift)

- In het aferese product worden meer circulerende tumor cellen vaker aangetoond dan in het perifere bloed van niet-kleincellig long carcinoom patiënten. (dit proefschrift)

- Verandering in het aantal CTC in het aferese product na behandeling, weerspiegelt de tumor response op therapie. (dit proefschrift)

- Technologie is de beperkende factor in het verwerken van grote volumina DLA product. (dit proefschrift)

- In het DLA product kan het ISET systeem meer CTC aantonen dan andere technieken. (dit proefschrift)

- Circulerende epitheliale cellen aangetoond in de pulmonale vene tijdens een longoperatie, zijn slechts voor een klein deel van maligne oorsprong. (dit proefschrift)

- Klaring van de circulerende tumorcellen vind niet (alleen) plaats in de microcirculatie, maar voornamelijk centraal. (dit proefschrift)

- Immuun cel fracties geassocieerd met een betere overleving voor patiënten met

adenocarcinoom, kunnen juist geassocieerd zijn met slechtere overleving voor patiënten met plaveisel cel carcinoom. (dit proefschrift)

- Rokers hebben verhoogde immuun cel fracties geassocieerd met kortere overleving. (dit proefschrift)

- De expressie van vijf genen is voldoende om in 95% van de gevallen te identificeren welk subtype longkanker een patiënt heeft. (dit proefschrift)

- Tumorcellen van longkanker patienten hebben een defect in de antigeen presentatie. (dit proefschrift)

- Success is going from failure to failure without losing enthusiasm (anonymous) - There are three kinds of lies: lies, damned lies, and statistics. (Benjamin Disraeli)

- United wishes and good will cannot overcome brute facts. Truth is incontrovertible. Panic may resent it. Ignorance may deride it. Malice may distort it. But there it is. (Winston Churchil)

Referenties

GERELATEERDE DOCUMENTEN

Chapter 4 Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. Journal for immunotherapy

PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system.

We studied the relation between overall survival (OS) and the presence of four cancer biomarkers from a single blood draw in advanced NSCLC patients: EpCAM high circulating

In this study we showed that the presence of CTC before therapy is a risk factor for worse tumor response rates and survival in advanced non-small cell lung cancer, irrespective

Percentage of advanced non-small cell lung cancer (NSCLC) patients with an early response (partial and complete response according to the revised response evaluation criteria in

For patients undergoing an open thoracotomy, 7.5 mL of blood was drawn from the radial artery at the start of surgery (baseline, T0), followed by blood draws from both the

Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients.. Chapter

The question remains whether alterations in HPA axis are the result of abnormal pain perception or that CP can be seen as a consequence of HPA axis dysfunction (Adler &